BTD
CRSP icon

BankPlus Trust Department’s CRISPR Therapeutics CRSP Stock Holding History

BankPlus Trust Department’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.76K Hold
100
– – ﹤0.01% 409
2025
Q4 		$5.24K Hold
100
– – ﹤0.01% 402
2025
Q3 		$6.48K Hold
100
– – ﹤0.01% 382
2025
Q2 		$4.86K Hold
100
– – ﹤0.01% 386
2025
Q1 		$3.4K Buy
+100
New +$4.24K ﹤0.01% 420

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BankPlus Trust Department's CRSP Position: Q1 2026 in Review

BankPlus Trust Department held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 100 shares worth $4.76K. The position accounts for ﹤0.01% of the portfolio, ranked #409.

BankPlus Trust Department first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.48K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • BankPlus Trust Department held 100 shares of CRISPR Therapeutics worth $4.76K as of Q1 2026.
  • BankPlus Trust Department left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of BankPlus Trust Department's portfolio in Q1 2026, its #409 holding.
  • BankPlus Trust Department first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • BankPlus Trust Department's CRISPR Therapeutics position peaked at $6.48K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on BankPlus Trust Department's 13F filing for Q1 2026, filed 11 May 2026.